CordenPharma Expands Sterile Injectable Capacity to Meet Rising Global Demand

CordenPharma's Significant Capacity Expansion in Sterile Injectables

CordenPharma, a prominent contract development and manufacturing organization (CDMO), is ramping up its sterile injectable manufacturing capabilities with an investment of €80 million at its FDA and EMA-approved production site in Caponago, Italy. With this major augmentation, the company is set to bolster its capacity to produce up to 500 million sterile injectable units per year, responding to the increasing global demand for these essential drugs.

This strategic expansion consists of two main components. First, in July 2026, CordenPharma acquired a brand new commercial building covering 11,000 m², along with an adjacent 26,000 m² of land. This acquisition enhances the existing aseptic fill-finish manufacturing area by over 50%. The newly established facility is designed as a versatile space, ready to accommodate a variety of injectable formats, including Pre-Filled Syringes (PFS), vials, and cartridges, as well as advanced auto-injectors. This significant step places CordenPharma at the forefront of pharmaceutical manufacturing by allowing flexibility for various production requirements, while also supporting a seamless integration of manufacturing lines.

In addition to the new facility, CordenPharma has implemented a series of strategic upgrades to its existing infrastructure in Caponago over the past two years. This included the installation of two new aseptic fill-finish isolator lines, which cater specifically to clinical and small-scale commercial productions. A notable highlight among the new facilities is a high-speed production line for Pre-Filled Syringes and cartridges by Syntegon, designed to produce over 500,000 units daily.

Moreover, the expansion also includes the enhancement of secondary packaging capabilities alongside the doubling of analytical capacity to support growing project pipelines. The completion of these facilities is projected for mid-2027 and 2028, ensuring CordenPharma maintains its commitment to sterility assurance and compliance in sterile injectable manufacturing.

The proactive investment strategy by CordenPharma is a direct response to the urgent needs of global healthcare, particularly in therapeutic areas like oncology, obesity, and diabetes, where the demand for specialized injectable solutions is on the rise. Additionally, therapies involving complex modalities such as peptide-based GLP-1 treatments and oligonucleotides are becoming increasingly prevalent, necessitating robust manufacturing capabilities.

CordenPharma's integrated approach ensures that customers benefit from comprehensive solutions spanning the entire drug development lifecycle—from initial phases to large-scale production—anchored by the company's extensive expertise in various modalities including peptides, small molecules, and biologics.

Dr. Michael Quirmbach, President and CEO of CordenPharma Group, highlighted the significant role this expansion plays in reinforcing their leadership position in the manufacture of complex drug products. He emphasized the importance of these strategic investments, noting that the backing from shareholders, such as Astorg, has been pivotal in driving forward the capabilities in sterile injectable manufacturing. This also positions CordenPharma to aid innovators in delivering critical therapies to patients more efficiently.

With 13 facilities distributed across Europe, North America, and Asia, CordenPharma stands as a global leader in CDMO services, dedicated to supporting biotech and pharmaceutical innovators in navigating complex drug development efficiently. For more information, visit CordenPharma's website or follow them on LinkedIn to stay updated on their advancements.